Home › Companies › PROTAGONIST THERAPEUTICS INC. › 2023-2024

PROTAGONIST THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and PROTAGONIST THERAPEUTICS INC.’s Form 8-K, filed 2024-06-26 (Item 5.07 on EDGAR). Page generated 04 October 2026.

6Ballot items
209Asset managers
1,451Fund votes
2024-06-20Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore PROTAGONIST THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by PROTAGONIST THERAPEUTICS INC.

These tallies are PROTAGONIST THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-26 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

PROTAGONIST THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-06-20
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Sarah A. O’Dowd	23,937,874	--	--	19,687,632	6,186,924	Majority: yes
Elect Director: William D. Waddill	40,485,630	--	--	3,139,876	6,186,924	Majority: yes
Elect Director: Lewis T. “Rusty” Williams, M.D., Ph.D.	41,412,428	--	--	2,213,078	6,186,924	Majority: yes
Proposal 2: To approve, on an advisory basis, the compensation of the Company's named executive officers	33,929,884	9,335,699	359,923	--	6,186,924	Passed
Proposal 3: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2024	49,293,711	115,292	403,427	--	--	Passed
Proposal 4: To approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of Common Stock from 90,000,000 to 180,000,000	47,200,237	278,523	2,333,670	--	--	Passed

Source: PROTAGONIST THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-26 — read the filing on EDGAR.

How asset managers voted at the PROTAGONIST THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 209 asset managers that disclosed a PROTAGONIST THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on an advisory basis, the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Combines 6 wordings of this item as funds reported it.

78% Passed · of votes cast

FOR 78%AGAINST 22%

FOR: 33,929,884AGAINST: 9,335,699

PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Proposal 2: To approve, on an advisory basis, the compensation of the Company's named executive officers”): 33,929,884 for, 9,335,699 against — passed, per its Form 8-K filed 2024-06-26 (Item 5.07). Of all 58,600,787 outstanding shares: 58% for, 16% against (74% of the company cast a for/against vote).

The 208 asset managers below cast 80% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 78%AGAINST 19%

FOR: 78.0%AGAINST: 19.3%ABSTAIN: 2.7%NOT VOTED: 0.0%

Largest asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers.” at PROTAGONIST THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
FARALLON CAPITAL MANAGEMENT LLC	0	5,605,285	0	Against
State Street	5,044,397	1,059	0	For
BlackRock	4,929,646	13,787	0	For
BVF INC/IL	3,566,270	0	0	For
Vanguard	3,197,486	0	0	For
RTW INVESTMENTS, LP	2,817,667	0	0	For
Johnson & Johnson Innovation - JJDC, Inc.	2,449,183	0	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	2,238,868	0	0	For
Fidelity	1,236,701	932,551	0	For
T. Rowe Price	1,460,706	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,299,437	0	0	For
Kynam Capital Management, LP	0	0	1,013,018	Abstain
Charles Schwab	1,005,672	0	0	For
Fairmount Funds Management LLC	931,890	0	0	For
Point72	719,781	0	0	For
683 Capital Management, LLC	700,000	0	0	For
MARSHALL WACE, LLP	0	665,424	0	Against
Woodline Partners LP	541,387	0	0	For
Nuveen	536,209	0	0	For
Dimensional	0	531,487	0	Against
TIAA	473,993	0	0	For
Northern Trust	460,666	39	0	For
PERCEPTIVE ADVISORS LLC	440,226	0	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	438,690	0	0	For
UBS	42,587	359,355	0	Against

Showing the 25 largest of 208 asset managers. See all 208 in the interactive database.

2. To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock from 90,000,000 to 180,000,000.

CAPITAL STRUCTURECompany result: Passed

Combines 4 wordings of this item as funds reported it.

99.4% Passed · of votes cast

FOR 99.4%

FOR: 47,200,237AGAINST: 278,523

PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Proposal 4: To approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of Common Stock from 90,000,000 to 180,000,000”): 47,200,237 for, 278,523 against — passed, per its Form 8-K filed 2024-06-26 (Item 5.07). Of all 58,600,787 outstanding shares: 81% for, 0.5% against (81% of the company cast a for/against vote).

The 66 asset managers below cast 99.9% of the shares they voted on this item FOR (13,691,114 for, 78 against).

FOR 93%

FOR: 13,691,114 (93.1%)AGAINST: 78 (0.0%)ABSTAIN: 1,013,018 (6.9%)

Largest asset managers voting on “To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our” at PROTAGONIST THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	3,074,193	0	0	For
BlackRock	3,065,574	0	0	For
State Street	1,961,562	78	0	For
Fidelity	1,701,400	0	0	For
Kynam Capital Management, LP	0	0	1,013,018	Abstain
T. Rowe Price	624,514	0	0	For
Charles Schwab	502,836	0	0	For
TIAA	473,993	0	0	For
Dimensional	425,437	0	0	For
First Trust	154,672	0	0	For
Equitable	152,721	0	0	For
Direxion Shares ETF Trust	130,315	0	0	For
JPMorgan	127,662	0	0	For
CARILLON SERIES TRUST	113,922	0	0	For
QUANTITATIVE MASTER SERIES LLC	106,465	0	0	For
Lincoln Financial	89,839	0	0	For
American Century	87,424	0	0	For
SEI	70,414	0	0	For
Nushares ETF Trust	58,621	0	0	For
John Hancock	52,508	0	0	For
ProShares	49,787	0	0	For
Exchange Place Advisors Trust	49,238	0	0	For
Prudential/PGIM	48,353	0	0	For
DRIEHAUS MUTUAL FUNDS	45,028	0	0	For
ALPS ETF Trust	40,780	0	0	For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

3. To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

AUDIT-RELATEDCompany result: Passed

Combines 3 wordings of this item as funds reported it.

99.7% Passed · of votes cast

FOR 99.7%

FOR: 49,293,711AGAINST: 115,292

PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Proposal 3: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2024”): 49,293,711 for, 115,292 against — passed, per its Form 8-K filed 2024-06-26 (Item 5.07). Of all 58,600,787 outstanding shares: 84% for, 0.2% against (84% of the company cast a for/against vote).

The 64 asset managers below cast 100% of the shares they voted on this item FOR (13,651,692 for, 0 against).

FOR 100%

FOR: 13,651,692 (100.0%)

Largest asset managers voting on “To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fisc” at PROTAGONIST THERAPEUTICS INC., 2023-2024
Asset manager	For	Vote
Vanguard	3,074,193	For
BlackRock	3,065,574	For
State Street	1,961,640	For
Fidelity	1,701,400	For
T. Rowe Price	624,514	For
Charles Schwab	502,836	For
TIAA	473,993	For
Dimensional	425,437	For
First Trust	154,672	For
Equitable	152,721	For
Direxion Shares ETF Trust	130,315	For
JPMorgan	127,662	For
CARILLON SERIES TRUST	113,922	For
QUANTITATIVE MASTER SERIES LLC	106,465	For
Lincoln Financial	89,839	For
American Century	87,424	For
SEI	70,414	For
Nushares ETF Trust	58,621	For
John Hancock	52,508	For
ProShares	49,787	For
Exchange Place Advisors Trust	49,238	For
Prudential/PGIM	48,353	For
DRIEHAUS MUTUAL FUNDS	45,028	For
ALPS ETF Trust	40,780	For
Pacific Life	40,067	For

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

4. To elect the Class II director nominees named below to hold office until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Lewis T. "Rusty" Williams, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 41,412,428WITHHELD: 2,213,078

PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Elect Director: Lewis T. “Rusty” Williams, M.D., Ph.D.”): 41,412,428 for, 2,213,078 withheld, per its Form 8-K filed 2024-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,600,787 outstanding shares: 71% for, 4% withheld (74% of the company cast a for/withheld vote).

The 62 asset managers below cast 100% of the shares they voted on this item FOR (12,673,842 for, 0 against).

FOR 93%7%

FOR: 12,673,842 (92.9%)ABSTAIN: 964,151 (7.1%)

Largest asset managers voting on “To elect the Class II director nominees named below to hold office until the 2027 Annual Meeting of Stockholde” at PROTAGONIST THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	3,074,193	0	For
BlackRock	3,065,574	0	For
State Street	1,961,466	174	For
Fidelity	1,236,701	464,699	For
T. Rowe Price	624,514	0	For
Charles Schwab	502,836	0	For
TIAA	473,993	0	For
Dimensional	0	425,437	Abstain
First Trust	154,672	0	For
Equitable	98,521	54,200	For
Direxion Shares ETF Trust	130,315	0	For
JPMorgan	127,662	0	For
CARILLON SERIES TRUST	113,922	0	For
QUANTITATIVE MASTER SERIES LLC	106,465	0	For
Lincoln Financial	83,932	5,907	For
American Century	87,424	0	For
SEI	70,414	0	For
Nushares ETF Trust	58,621	0	For
John Hancock	52,508	0	For
ProShares	49,787	0	For
Exchange Place Advisors Trust	49,238	0	For
Prudential/PGIM	48,353	0	For
DRIEHAUS MUTUAL FUNDS	45,028	0	For
ALPS ETF Trust	40,780	0	For
Pacific Life	40,067	0	For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

5. To elect the Class II director nominees named below to hold office until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Sarah A. O'Dowd

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

54.9% Majority: yes · of votes cast

FOR 54.9%WITHHELD 45.1%

FOR: 23,937,874WITHHELD: 19,687,632

PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Elect Director: Sarah A. O’Dowd”): 23,937,874 for, 19,687,632 withheld, per its Form 8-K filed 2024-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,600,787 outstanding shares: 41% for, 34% withheld (74% of the company cast a for/withheld vote).

The 62 asset managers below cast 100% of the shares they voted on this item FOR (8,574,625 for, 0 against).

FOR 63%ABSTAIN 37%

FOR: 8,574,625 (62.9%)ABSTAIN: 5,063,368 (37.1%)

Largest asset managers voting on “To elect the Class II director nominees named below to hold office until the 2027 Annual Meeting of Stockholde” at PROTAGONIST THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	3,070,415	3,778	For
BlackRock	3,065,574	0	For
State Street	2,055	1,959,585	Abstain
Fidelity	1,233,801	467,599	For
T. Rowe Price	624,514	0	For
Charles Schwab	0	502,836	Abstain
TIAA	0	473,993	Abstain
Dimensional	0	425,437	Abstain
First Trust	0	154,672	Abstain
Equitable	98,521	54,200	For
Direxion Shares ETF Trust	0	130,315	Abstain
JPMorgan	127,662	0	For
CARILLON SERIES TRUST	0	113,922	Abstain
QUANTITATIVE MASTER SERIES LLC	106,465	0	For
Lincoln Financial	9,905	79,934	Abstain
American Century	0	87,424	Abstain
SEI	0	70,414	Abstain
Nushares ETF Trust	0	58,621	Abstain
John Hancock	31,501	21,007	For
ProShares	0	49,787	Abstain
Exchange Place Advisors Trust	0	49,238	Abstain
Prudential/PGIM	48,353	0	For
DRIEHAUS MUTUAL FUNDS	0	45,028	Abstain
ALPS ETF Trust	0	40,780	Abstain
Pacific Life	40,067	0	For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

6. To elect the Class II director nominees named below to hold office until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: William D. Waddill

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%

FOR: 40,485,630WITHHELD: 3,139,876

PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Elect Director: William D. Waddill”): 40,485,630 for, 3,139,876 withheld, per its Form 8-K filed 2024-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,600,787 outstanding shares: 69% for, 5% withheld (74% of the company cast a for/withheld vote).

The 62 asset managers below cast 100% of the shares they voted on this item FOR (12,673,842 for, 0 against).

FOR 93%7%

FOR: 12,673,842 (92.9%)ABSTAIN: 964,151 (7.1%)

Largest asset managers voting on “To elect the Class II director nominees named below to hold office until the 2027 Annual Meeting of Stockholde” at PROTAGONIST THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	3,074,193	0	For
BlackRock	3,065,574	0	For
State Street	1,961,466	174	For
Fidelity	1,236,701	464,699	For
T. Rowe Price	624,514	0	For
Charles Schwab	502,836	0	For
TIAA	473,993	0	For
Dimensional	0	425,437	Abstain
First Trust	154,672	0	For
Equitable	98,521	54,200	For
Direxion Shares ETF Trust	130,315	0	For
JPMorgan	127,662	0	For
CARILLON SERIES TRUST	113,922	0	For
QUANTITATIVE MASTER SERIES LLC	106,465	0	For
Lincoln Financial	83,932	5,907	For
American Century	87,424	0	For
SEI	70,414	0	For
Nushares ETF Trust	58,621	0	For
John Hancock	52,508	0	For
ProShares	49,787	0	For
Exchange Place Advisors Trust	49,238	0	For
Prudential/PGIM	48,353	0	For
DRIEHAUS MUTUAL FUNDS	45,028	0	For
ALPS ETF Trust	40,780	0	For
Pacific Life	40,067	0	For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

Largest PROTAGONIST THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of PROTAGONIST THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 58,600,787 shares outstanding at the time of that meeting.

Top PROTAGONIST THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	FARALLON CAPITAL MANAGEMENT LLC	9.57%
2	State Street	8.61%
3	BlackRock	8.44%
4	BVF INC/IL	6.09%
5	Vanguard	5.46%
6	RTW INVESTMENTS, LP	4.81%
7	Johnson & Johnson Innovation - JJDC, Inc.	4.18%
8	ADAGE CAPITAL PARTNERS GP, L.L.C.	3.82%
9	Fidelity	3.70%
10	T. Rowe Price	2.49%

Reported PROTAGONIST THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

PROTAGONIST THERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
BlackRock	16.05%	13F
Vanguard Group	7.26%	13F
State Street	5.58%	13F
Geode Capital	2.21%	13F
Point72	2.05%	13F
T. Rowe Price	1.40%	13F
Dimensional Fund Advisors	1.35%	13F
Goldman Sachs	1.33%	13F
Morgan Stanley	1.31%	13F
Nuveen	1.16%	13F

Percentages above are of 58,600,787 shares outstanding, as reported by PROTAGONIST THERAPEUTICS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PROTAGONIST THERAPEUTICS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At PROTAGONIST THERAPEUTICS INC.'s shareholder meeting held 2024-06-20, in the 2023-2024 proxy season, 209 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,451 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers. — the proposal passed with 78% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: PROTAGONIST THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-26.

PROTAGONIST THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.